Demand for injectable medicines keeps rising, and SCHOTT Pharma aims to ride that wave by selling more premium, higher‑value packaging used in newer therapies. The upside comes from fast new factory ramp-ups and a push into greener materials, but investors should watch for weak demand in core products, heavy spending, and reliance on a small group of big drugmakers.Read more
A behind-the-scenes supplier to injectable drug makers is betting on newer packaging and delivery formats, plus big factory buildouts, to win more of the next wave of complex medicines. The catch is that some core product lines are soft and the company is spending heavily while facing leadership change and uncertain demand in parts of its syringe business.Read more
SCHOTT Pharma sells packaging and delivery parts for injectable medicines, but tougher climate rules, trade barriers, and cheaper rivals could squeeze its profits and slow its growth. At the same time, changes in how medicines are taken and where drugmakers want to source supplies may reshape which markets it can win next.Read more
No trending discussion available.
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
